Article
Medicine, Research & Experimental
Jingwen Yuan, Shahid Ullah Khan, Junfeng Yan, Jiatong Lu, Chen Yang, Qiang Tong
Summary: Baicalin inhibits gastric cancer and enhances the efficacy of 5-Fu by promoting ROS-related ferroptosis in gastric cancer.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Pharmacology & Pharmacy
Jingyi Hu, Anqi Li, Yueyang Guo, Ting Ma, Siqi Feng
Summary: This review summarizes the main tumor metabolic alterations linked with 5-FU resistance and proposes potential chemotherapy combinations from the perspective of intervening tumor metabolism to overcome 5-FU resistance.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Pathology
Yu-Ling Qu, Xiao-Li Liu, Shan-Yu Zhao, Xue-Feng Zhai
Summary: This study found that SPOCK1 is upregulated in 5-FU-resistant CRC cells and that knockdown of SPOCK1 increases their sensitivity to 5-FU. Conversely, overexpression of SPOCK1 enhances CRC cell resistance to 5-FU and reduces cell apoptosis.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Review
Biochemistry & Molecular Biology
Fahima Danesh Pouya, Maria Gazouli, Yousef Rasmi, Dimitra Ioanna Lampropoulou, Mohadeseh Nemati
Summary: Colorectal cancer is a common cancer, and drug resistance is a major cause of chemotherapy failure and disease recurrence. Many studies have identified mechanisms that contribute to chemoresistance in colorectal cancer, and microRNAs may serve as potential therapeutic targets or biomarkers for predicting drug response.
MOLECULAR BIOLOGY REPORTS
(2022)
Article
Biochemistry & Molecular Biology
Chinatsu Kurasaka, Yoko Ogino, Akira Sato
Summary: This study identified that 5-FU-resistant cells exhibit increased TS expression and utilize the TS enzyme to trap the active metabolite FdUMP, resulting in resistance to 5-FU and its analogs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Engineering, Biomedical
Eun-Jeong Won, Hyeji Park, Seung-Hee Chang, Jin Hyun Kim, Hojeong Kwon, Young-Seok Cho, Tae-Jong Yoon
Summary: Diagnosing patients with pancreatic ductal adenocarcinoma (PDAC) early on can be challenging, with treatment often being complex. Gemcitabine (GEM) is the first-line treatment for PDAC, but its efficacy is limited in most patients due to resistance caused by mutations in the KRAS and P53 genes. This study explores the correction of double gene mutations and therapeutic effects for GEM-resistant PDAC. By utilizing bioavailable nanoliposomes (NL) carrying Cas9-ribonucleoproteins and adenine-base editors for gene editing, a potent therapy for PDAC, potentially overcoming chemoresistance, is proposed.
Article
Biochemistry & Molecular Biology
C. Arnold Spek, Hella L. Aberson, JanWillem Duitman
Summary: This study identifies C/EBP delta as an important transcription factor driving macrophage-induced gemcitabine resistance in pancreatic cancer cells.
Review
Oncology
Jose J. G. Marin, Maria J. Monte, Rocio I. R. Macias, Marta R. Romero, Elisa Herraez, Maitane Asensio, Sara Ortiz-Rivero, Candela Cives-Losada, Silvia Di Giacomo, Javier Gonzalez-Gallego, Jose L. Mauriz, Thomas Efferth, Oscar Briz
Summary: Hepatobiliary, pancreatic, and gastrointestinal cancers account for 36% of the approximately 10 million cancer-related deaths worldwide each year. One primary reason for this high mortality is the lack of response of these cancers to pharmacological treatment. More than 100 genes have been identified as responsible for seven mechanisms of chemoresistance, but only a few play a critical role, including ABC proteins (mainly MDR1, MRP1-6, and BCRP), whose expression pattern greatly determines individual tumor sensitivity to pharmacotherapy.
Review
Chemistry, Medicinal
Anai A. Valencia-Lazcano, Dilawar Hassan, Mehrab Pourmadadi, Amin Shamsabadipour, Razieh Behzadmehr, Abbas Rahdar, Dora I. Medina, Ana M. Diez-Pascual
Summary: This study reviews the applications of 5-Fluorouracil (5-FU) as an anticancer drug for various types of cancers. Different approaches, such as nanoparticles loaded with 5-FU, co-delivery systems with other drugs, have been described to overcome the limitations of 5-FU therapy. This review provides the latest progress on 5-FU-loaded nanocarriers and their potential as an advanced tool for cancer therapy.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Pharmacology & Pharmacy
Annie Cristhine Moraes Sousa-Squiavinato, Diego Alfonso Arregui Ramos, Monica Silveira Wagner, Josiane Weber Tessmann, Julio Cesar Madureira de-Freitas-Junior, Jose Andres Morgado-Diaz
Summary: A long-term drug-resistant colorectal cancer model was established to explore the cellular events underlying 5-fluorouracil (5FU) resistance. The study identified various cellular events and molecular changes associated with 5FU resistance, as well as specific genes that could predict poor outcomes in colorectal cancer patients. The findings highlight the importance of identifying promising targets involved in multiple cellular events to overcome drug resistance.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Mariana Pereira, Nuno Vale
Summary: The study found that saquinavir (SAQ) in combination with 5-fluorouracil (5-FU) had a better synergistic effect in treating prostate cancer cells (PC-3) than in treating lung cancer cells (A549).
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Yoshihiko Tasaki, Miho Suzuki, Keisuke Katsushima, Keiko Shinjo, Kenta Iijima, Yoshiteru Murofushi, Aya Naiki-Ito, Kazuki Hayashi, Chenjie Qiu, Akiko Takahashi, Yoko Tanaka, Tokuichi Kawaguchi, Minoru Sugawara, Tomoya Kataoka, Mitsuru Naito, Kanjiro Miyata, Kazunori Kataoka, Tetsuo Noda, Wentao Gao, Hiromi Kataoka, Satoru Takahashi, Kazunori Kimura, Yutaka Kondo
Summary: The study shows that targeting TUG1 can impact the sensitivity of pancreatic cancer cells to 5-FU, and treatment with TUG1-DDS can effectively suppress PDAC tumor growth. This novel approach may offer a new combinatorial strategy for cancer treatment.
Article
Biochemistry & Molecular Biology
Yun Chen, Bocheng Zhang, Cui Zhong, Yuqing Zhou, Lei Xue, Chenhui Luo, Liang Yi, Qian Gong, Ying Long
Summary: This study reveals the important regulatory role of the let-7g/ABCC10 axis in the 5-FU resistance of liver cancer cells. By downregulating ABCC10 expression, prolonging the G1 phase, and promoting apoptosis, let-7g enhances the sensitivity of liver cancer cells to 5-FU.
CHEMICAL BIOLOGY & DRUG DESIGN
(2023)
Article
Multidisciplinary Sciences
Daniel R. Principe, Alexandre F. Aissa, Sandeep Kumar, Thao N. D. Pham, Patrick W. Underwood, Rakesh Nair, Rong Ke, Basabi Rana, Jose G. Trevino, Hidayatullah G. Munshi, Elizaveta Benevolenskaya, Ajay Rana
Summary: There is currently no effective treatment for pancreatic ductal adenocarcinoma (PDAC). In this study, researchers identified a subset of gemcitabine-resistant tumor cells enriched for calcium/calmodulin signaling. Inhibition of calcium-dependent calmodulin activation led to the loss of drug-resistant phenotypes, and calcium chelation or depletion impaired ERK activation and restored therapeutic responses to gemcitabine. Calcium channel blockers also enhanced therapeutic responses to gemcitabine.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Oncology
Tomonari Suetsugu, Ryutaro Mori, Manabu Futamura, Masahiro Fukada, Hideharu Tanaka, Itaru Yasufuku, Yuta Sato, Yoshinori Iwata, Takeharu Imai, Hisashi Imai, Yoshihiro Tanaka, Naoki Okumura, Nobuhisa Matsuhashi, Takao Takahashi, Kazuhiro Yoshida
Summary: Fluorouracil (5FU) is converted to its active metabolite fluoro-deoxyuridine monophosphate (FdUMP) through different pathways in different cells, contributing to varying mechanisms of resistance. When overcoming 5FU resistance, both the synthesized amount of FdUMP and sensitivity to FdUMP should be taken into consideration.
Article
Oncology
Graeme C. Fielder, Teresa Wen-Shan Yang, Mahalakshmi Razdan, Yan Li, Jun Lu, Jo K. Perry, Peter E. Lobie, Dong-Xu Liu
Article
Oncology
Tarek M. A. Abdel-Fatah, Reuben J. Broom, Jun Lu, Paul M. Moseley, Baiqu Huang, Lili Li, Suling Liu, Longxin Chen, Runlin Z. Ma, Wenming Cao, Xiaojia Wang, Yan Li, Jo K. Perry, Mohammed Aleskandarany, Christopher C. Nolan, Emad A. Rakha, Peter E. Lobie, Stephen Y. T. Chan, Ian O. Ellis, Le-Ann Hwang, David P. Lane, Andrew R. Green, Dong-Xu Liu
BRITISH JOURNAL OF CANCER
(2019)
Article
Multidisciplinary Sciences
Khine Myint, Riya Biswas, Yan Li, Nancy Jong, Stephen Jamieson, Johnson Liu, Catherine Han, Christopher Squire, Fabrice Merien, Jun Lu, Takeo Nakanishi, Ikumi Tamai, Mark McKeage
SCIENTIFIC REPORTS
(2019)
Article
Oncology
Tamkin Ahmadzada, Kenneth Lee, Candice Clarke, Wendy A. Cooper, Anthony Linton, Brian McCaughan, Rebecca Asher, Stephen Clarke, Glen Reid, Steven Kao
Article
Oncology
Riya Biswas, Piyush Bugde, Ji He, Fabrice Merien, Jun Lu, Dong-Xu Liu, Khine Myint, Johnson Liu, Mark McKeage, Yan Li
Article
Oncology
Thomas G. Johnson, Karin Schelch, Kaitao Lai, Kamila A. Marzec, Marina Kennerson, Michael Grusch, Glen Reid, Andrew Burgess
Review
Oncology
Jiawei Li, Xin Guan, Zhimin Fan, Lai-Ming Ching, Yan Li, Xiaojia Wang, Wen-Ming Cao, Dong-Xu Liu
Article
Chemistry, Medicinal
Siting Li, Zhangli Hu, Xuewei Yang, Yan Li
Review
Biochemistry & Molecular Biology
Ji He, Erika Fortunati, Dong-Xu Liu, Yan Li
Summary: Chemotherapeutics are a main therapy for metastatic breast cancers, but multidrug resistance due to ABC transporters remains a challenge. Targeting ABCB1 to reverse drug resistance in clinical trials has been disappointing, but ABC transporters may play roles in breast cancer development and metastasis beyond efflux function. Understanding the functions and regulations of ABC transporters in breast cancer biology may lead to more targeted and novel therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Integrative & Complementary Medicine
Riya Biswas, Chun-mei Yang, Wei Lu, Ji He, Tony Chen, Fang Tian, Yan Li
Summary: The study demonstrated that Aidi injection enhanced gefitinib sensitivity in three NSCLC cell lines and increased gefitinib-induced apoptosis. Analysis showed that high expression of the ABCC2 gene was associated with significantly poorer survival in lung adenocarcinoma patients. Additionally, docking studies suggested that Ginsenoside_Re in Aidi injection could potentially inhibit MRP2.
EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Ji He, Riya Biswas, Piyush Bugde, Jiawei Li, Dong-Xu Liu, Yan Li
Summary: CRISPR-Cas9 is widely used in genome editing and provides several advantages for studying the interactions between membrane proteins and drugs. However, there are still challenges and issues to be addressed in CRISPR-Cas9 gene editing.
Article
Oncology
Ben Johnson, Ling Zhuang, Emma M. Rath, Man Lee Yuen, Ngan Ching Cheng, Huaikai Shi, Steven Kao, Glen Reid, Yuen Yee Cheng
Summary: Malignant pleural mesothelioma (MPM) is a deadly thoracic malignancy with limited treatment options. Chemotherapy is the most common treatment, but drug resistance is a challenge. MicroRNA transfection can enhance MPM cell sensitivity to chemotherapy drugs, and influence the response to survivin (YM155) small molecule inhibitor treatment.
Review
Biology
Jiawei Li, Eyleen L. K. Goh, Ji He, Yan Li, Zhimin Fan, Zhigang Yu, Peng Yuan, Dong-Xu Liu
Summary: Breast cancer is the most common cancer worldwide and the leading cause of cancer-related death in women. Although survival rates have improved for early-stage breast cancer patients, those with advanced or metastatic breast cancer still have low survival rates, necessitating the development of new therapies. Mechanistic insights into metastatic breast cancer have provided opportunities for developing novel therapeutic strategies. This review summarizes the emerging therapeutic targets for metastatic breast cancer, including various signaling pathways, growth factor receptors, immune checkpoint proteins, and breast cancer stem cells. Therapeutic drugs targeting these molecules/pathways are either FDA-approved or under clinical trial.
